LONDON--(BUSINESS WIRE)--Jul 25, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat diabetic neuropathy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180725005684/en/
Technavio has published a new report on the drug development pipeline for diabetic neuropathy, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Diabetic neuropathy: Market overview
Diabetic neuropathy is a type of nerve damage caused by diabetes. Over time, hyperglycemia and high levels of fats can damage nerves. Neuropathy can be caused by both type 1 and type 2 diabetes. Furthermore, diabetic neuropathy is classified into peripheral neuropathy, proximal neuropathy, autonomic neuropathy, and focal neuropathy. The pathogenesis of diabetic neuropathy is complex and is marked by both metabolic and vascular factors including hyperglycemia, toxic adiposity, oxidative stress, mitochondrial dysfunction, activation of the polyol pathway, accumulation of advanced glycation end products, and elevation of inflammatory markers.
According to a senior market research analyst at Technavio, “According to the Centers for Disease Control and Prevention, around 60-70% of people with diabetes have diabetic neuropathy. The highest number of neuropathic problems are among the people who have had diabetes for at least 25 years. Also, diabetic nerve problems are more common in people who have problems in controlling their blood glucose levels, weight, and blood pressure.”
Diabetic neuropathy: Segmentation analysis
This pipeline analysis report segments the diabetic neuropathy market based on therapies employed (monotherapy and combination therapy), RoA (oral, topical, intramuscular, and intravenous), therapeutic modality (small molecule, peptide, biological, monoclonal antibody, cell therapy, antibody, rhIL-6, and gene therapy), targets (calcium channel, cannabinoid receptor type 2, TRPV1, and others), MoA (calcium channel blocker, cannabinoid receptor type 2 agonist, and others), geographical segmentation (US, Hungary, Japan, South Korea, Poland, Taiwan, Austria, Germany and others) and recruitment status (active, not recruiting, completed, planned, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 46% of the molecules that are being investigated for the treatment of diabetic neuropathy are small molecule.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180725005684/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL DIABETES
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/25/2018 01:18 PM/DISC: 07/25/2018 01:18 PM